Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

INTRODUCTION: The sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin is approved for the treatment of adults with type 2 diabetes mellitus (T2DM). This analysis was conducted on safety data pooled from phase 3 studies using ertugliflozin 5 mg or 15 mg versus placebo or an active comparat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Patel, Shrita, Hickman, Anne, Frederich, Robert, Johnson, Susan, Huyck, Susan, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7261307/
https://ncbi.nlm.nih.gov/pubmed/32372382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00803-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky